Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

License Agreements (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
License Agreements (Details) - USD ($) $ in Millions	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Oct. 31, 2025	Jan. 31, 2025	May 31, 2021	Oct. 31, 2020
2021 Xencor Agreement
Nature of Business
Regulatory milestone payments							$ 75.0
Sales milestone payments							385.0
License and option agreements, Food and Drug Administration market authorization payable							10.0
License and option agreements, Food and Drug Administration market authorization milestone payments made	$ 10.0
License and option agreements, Food and Drug Administration market approval payable							$ 20.0
Viridian Agreement
Nature of Business
Sales milestone payments								$ 21.0
Contract manufacturing organization costs recognized	0.0	$ 0.0	$ 0.0	$ 0.0
Reimbursable costs		$ 0.2		$ 0.2
Development milestone expense payable						$ 21.0
InnoCare Pharma Inc
Nature of Business
Non-refundable cash payment					$ 35.0
Number of shares agreed to be issued					5,000,000
Amount of contingent payment payable upon on occurrence of specified events					$ 25.0
Number of shares agreed to be issued upon on occurrence of specified events					2,000,000
Term milestone payments					$ 20.0
Future regulatory and commercial milestones payable					723.0
Development, regulatory and commercial milestones payable					636.0
Regulatory milestones payable					$ 20.0
Regulatory milestone payments made	20.0
Contract manufacturing organization costs recognized	0.7		1.9
Reimbursable costs	$ 1.4		$ 2.2